Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Shandong Buchang Pharmaceuticals Receives NMPA Approval for BC008-1A Biologic Product Clinical Trial

Fineline Cube Jul 10, 2024

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a pharmaceutical company based in China, has announced...

Company Drug

HOB Biotech Receives NMPA Approval for Clinical Trials of MM09 Sublingual Spray

Fineline Cube Jul 10, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced that it has received clinical...

Company Deals Medical Device

Hugo Biotech Partners with Watchmaker Genomics to Develop Infectious Disease Detection Solutions

Fineline Cube Jul 10, 2024

Hugo Biotech, a biotech company based in Beijing, has entered into a partnership with Watchmaker...

Company Deals

Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan

Fineline Cube Jul 9, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...

Company Deals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

Fineline Cube Jul 9, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Drug

Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall

Fineline Cube Jul 9, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...

Company Medical Device

Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval

Fineline Cube Jul 9, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment

Fineline Cube Jul 9, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights

Fineline Cube Jul 9, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...

Company Deals R&D

Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab

Fineline Cube Jul 9, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a...

Company Deals

China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria

Fineline Cube Jul 9, 2024

China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial

Fineline Cube Jul 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...

Company Drug

CSPC Pharmaceutical’s SYS6023 Receives FDA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 9, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC

Fineline Cube Jul 9, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...

Policy / Regulatory

China’s State Council Reportedly Approves Plan to Support Full Industry Chain of Innovative Drug Development

Fineline Cube Jul 8, 2024

A State Council executive meeting, chaired by Chinese Premier Li Qiang, reportedly approved an “Implementation...

Company Drug

AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China

Fineline Cube Jul 8, 2024

AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent

Fineline Cube Jul 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment

Fineline Cube Jul 8, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...

Company Drug

Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC

Fineline Cube Jul 8, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...

Company Drug

Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy

Fineline Cube Jul 8, 2024

Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...

Posts pagination

1 … 385 386 387 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.